Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Mothers may be eligible for this study if they:~* Have been pregnant for more than 32 weeks and are at least 18 years of age.~* Are HIV-positive.~* Reside within 15 km of Mulago Hospital, the study site.~* Infants may be eligible for this study if they:~* Are born to mothers enrolled in the study.~* Have consent of the mother/guardian and, if available, the father.~Exclusion Criteria~Mothers will not be eligible for this study if they:~* Have a serious infection or illness other than HIV.~* Currently take any anti-HIV drugs.~* Participate during this pregnancy in another treatment vaccine perinatal trial.~* Received NVP or AZT within the last 6 months.~* Are allergic to any benzodiazepine.~* Abuse alcohol or other drugs.~* Have high blood pressure that is not controlled.~* Have received any anticoagulants, benzodiazepines other than the study drug, or magnesium sulfate within 2 weeks before being assigned to a study group or delivery.~* Infants will not be eligible for this study if:~* Their mother is excluded prior to being assigned to a study group.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).